Understanding GI Effects Associated with GLP-1 Therapy

GLP-1 receptor agonists are widely used in metabolic disease management. Gastrointestinal side effects, particularly nausea and constipation, are commonly observed in clinical practice, especially during initiation and dose escalation.

Clinical Overview of GLP-1–Associated GI Effects

Nausea and constipation are among the most frequently reported gastrointestinal side effects associated with GLP-1 receptor agonists.1,2 These effects are generally most pronounced during treatment initiation and dose escalation and are thought to be related to delayed gastric emptying and central appetite regulation mechanisms.3 

Symptom severity and duration vary by patient, and many individuals experience improvement over time with continued therapy. However, tolerability challenges may influence patient experience and even halt GLP-1 therapy in some cases.4,5,6 

Proactive counseling, expectation setting, and follow-up during dose escalation may support improved tolerability in clinical practice.

Read More

Supporting Patients During GLP-1 Therapy

Clinical experience suggests that anticipatory counseling prior to initiation and during dose escalation may help set expectations regarding gastrointestinal effects.

Considerations in practice may include:

  • Gradual dose escalation strategies
  • Dietary modifications (smaller meals, reduced fat intake)
  • Hydration guidance
  • Ongoing symptom monitoring during titration

Regular follow-up may help identify patients who require additional supportive strategies.

Managing Common GI Symptoms in Practice

Nausea and constipation are common management considerations in patients receiving GLP-1 therapy.7 Supportive, non-prescription options may be discussed within broader symptom management strategies where clinically appropriate.

Download Study Results

In a double-blind, placebo-controlled pilot study conducted by Prestige Consumer Healthcare, post-dose nausea severity declined 3.7 points in participants randomized to Ginger vs. 3.0 points in participants randomized to Placebo (Figure).

The table shows Ginger reduced nausea severity in 96.2% of events while Placebo reduced nausea severity in only 83.0% of events (p<0.001, Chi-square test).

Advanced Herbals® Ginger Chews

Non-medicated, nausea relief in a delicious lemon-honey-ginger flavor in a convenient soft chew.

Learn More

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.
  2. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
  3. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251.
  4. Husain M, Birkenfeld AL, Donsmark M, et al. GLP-1s and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2019;381:841-51.
  5. Product insert: OZEMPIC (semaglutide) injection, for subcutaneous use. Initial U.S. approval: 2017.
  6. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2015;11(3):202–230.
  7. [SAMPLE] Additional reference.

Sources

  • Wegovy (semaglutide) injection [prescribing information]. Novo Nordisk Inc; 2024. Accessed June 2026. https://www.accessdata.fda.gov
  • Zepbound (tirzepatide) injection [prescribing information]. Eli Lilly and Company; 2024. Accessed June 2026. https://www.accessdata.fda.gov
  • American Diabetes Association. Standards of care in diabetes—2024. Diabetes Care. 2024;47(suppl 1).
  • Garvey WT, Mechanick JI, Brett EM, et al. AACE clinical practice guideline for the pharmacological management of obesity. Endocr Pract. 2022;28(9):923-1049.